Dyslipidemia beyond LDL
Dyslipidemie, meer dan alleen LDL
Many features of dyslipidemia are missed by the standard lipid panel. I investigated the use of advanced lipoprotein profiling in the diagnosis of dyslipidemia. I found that normoglycemic first degree relatives of type 2 diabetes (T2D) patients have lower high density lipoprotein (HDL) levels than controls from non T2D families. I also found that the drug lomitapide decreases all atherogenic lipoproteins, but does not affect HDL function.
Lipoprotein (a) (Lp(a)) is a risk factor for the development of cardiovascular disease (CVD), but there are no therapies available yet to solely reduce Lp(a) levels. I investigated the effect of widely used therapies aimed at CVD prevention on Lp(a). I found that both statin treatment and diet-induced weight reduction increase Lp(a) levels. I also found that Lp(a) is increased in heterozygous familial hypercholesterolemia (FH) and even more in homozygous FH compared to non-FH subjects. Future research will still have to define cut-off points for diabetic dyslipidemia using advanced lipoprotein profiling. It still remains to be clarified whether lowering of Lp(a) levels will eventually result in fewer CVD events.
|Keywords||Dyslipidemia, lipoprotein(a), HDL, FH, HoFH, T2D, lipoprotein profile|
|Promotor||E.J.G. Sijbrands (Eric) , M.T. Mulder (Monique) , J.E. Roeters van Lennep (Jeanine)|
|Publisher||Erasmus University Rotterdam|
|Note||For copyright reasons there is a partial embargo for this dissertation|
Yahya, R. (2019, March 13). Dyslipidemia beyond LDL. Erasmus University Rotterdam. Retrieved from http://hdl.handle.net/1765/115407